Safety of sildenafil for antidepressant-related sexual dysfunction.
Pies
R
R
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000493:pharmacokinetics; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D011687:Purines; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy*; D000068677:Sildenafil Citrate; D013450:Sulfones; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D065607:Cytochrome P-450 Enzyme Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014230:Triazoles; C051752:nefazodone; D003577:Cytochrome P-450 Enzyme System; D000068677:Sildenafil Citrate; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D015106:3',5'-Cyclic-GMP Phosphodiesterases